by The global Western Blotting Market is estimated to be valued at US$ 759.5 Mn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Western blotting is a technique used to detect specific proteins in a sample of tissue homogenate or extract. It uses gel electrophoresis to separate native or denatured proteins by the length of the polypeptide chain. The separated proteins are then transferred to a membrane, typically nitrocellulose or PVDF. The target protein is detected using a specifically bound known primary antibody which is then detected by a labeled secondary antibody or a direct labeled primary antibody. This technique is commonly used in biomedical research to investigate the expression of specific proteins as well as determine post-translational modifications. It allows rapid analysis of thousands of proteins simultaneously and is an important tool in proteomics.
Market key trends:
One of the key trends in the western blotting market is the increasing demand for automated western blotting systems. Automated systems offer advantages such as walk-away automation, higher throughput, better reproducibility and less manual errors. Major players are focusing on developing automated western blotting instruments with features such as minimal hands-on time required and transfer of more than one gel/membrane at once. Another trend is the use of western blotting technique for antibody-based assays used in various research activities such as proteomics and drug discovery. It plays a pivotal role in determining expression levels of target proteins and understanding various disease mechanisms. This extensive usage in research is expected to drive the growth of the global western blotting market during the forecast period.
Porter’s Analysis
Threat of new entrants: New players find it difficult to enter the Western Blotting market due to capital requirements for setting up manufacturing facilities and the established brand image of existing players.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of alternatives from global players and the possibility of shifting to substitutes to some extent.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the availability of alternative raw material suppliers and technical innovations that reduce dependence on specific suppliers.
Threat of new substitutes: Substitutes like ELISA are available but Western Blotting has applications that alternatives cannot replace fully, thereby posing a low threat from new substitutes.
Competitive rivalry: Intense due to presence of global established players leading to competition based on pricing, product quality and innovations.
Key Takeaways
The Global Western Blotting Market Size is expected to witness high growth, exhibiting CAGR of 6.8% over the forecast period, due to increasing R&D investments in drug discovery and increase in diagnostic procedures.
Regional analysis: North America dominated the market in 2023, accounting for the largest revenue share, owing to presence of key market players and advanced healthcare infrastructure in the region. Asia Pacific is expected to grow at the fastest pace during the forecast period with increasing biomedical research capabilities.
Key players operating in the Western Blotting are Thermo Fisher Scientific, Inc., GE HealthCare, F. Hoffmann-La Roche Ltd, Lumigen, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., LI-COR, Inc., Bio-Techne, SBH Sciences, Advansta Inc., Azure Biosystems Inc., HiMedia Laboratories., Elabscience Biotechnology Inc., GenScript, Cell Signaling Technology, Inc., ICL, Inc., Takara Bio Inc., Leinco Technologies. Key players are focused on product innovations and partnerships to strengthen their market presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
